Premium
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model
Author(s) -
Ignatoski K. M. Woods,
EscaraWilke J. F.,
Dai J.L.,
Lui A.,
Dougall W.,
Daignault S.,
Yao Z.,
Zhang J.,
Day M. L.,
Sargent E. E.,
Keller E. T.
Publication year - 2008
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20744
Subject(s) - docetaxel , medicine , rankl , prostate cancer , denosumab , bone metastasis , oncology , adjuvant , metastasis , cancer research , cancer , prostate , receptor , activator (genetics) , osteoporosis
BACKGROUND Docetaxel induces an anti‐tumor response in men with advanced prostate cancer (PCa); however, the side effects associated with docetaxel treatment can be severe, resulting in discontinuation of therapy. Thus, identification of an effective adjuvant therapy to allow lower doses of docetaxel is needed. Advanced PCa is typically accompanied by skeletal metastasis. Receptor activator of NFkB ligand (RANKL) is a key pro‐osteoclastic factor. Targeting RANKL decreases establishment and progression of PCa growth in bone in murine models. METHODS The efficacy of inhibiting RANKL, using a recombinant soluble RANK extracellular domain fused with the immunoglobulin Fc domain (RANK‐Fc), was tested as an adjuvant therapy with docetaxel for PCa bone metastasis in a murine intra‐tibial model. RESULT The combination of RANK‐Fc and docetaxel reduced tumor burden in bone greater than either treatment alone. CONCLUSION The combination of docetaxel with a RANKL‐inhibiting agent merits further investigation for treatment of advance PCa. Prostate 68:820–829, 2008. © 2008 Wiley‐Liss, Inc.